ES2774296T3 - Terapias de combinación para tratar cánceres quimiorresistentes - Google Patents
Terapias de combinación para tratar cánceres quimiorresistentes Download PDFInfo
- Publication number
- ES2774296T3 ES2774296T3 ES13851971T ES13851971T ES2774296T3 ES 2774296 T3 ES2774296 T3 ES 2774296T3 ES 13851971 T ES13851971 T ES 13851971T ES 13851971 T ES13851971 T ES 13851971T ES 2774296 T3 ES2774296 T3 ES 2774296T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- cancer
- formula
- hypomethylating agent
- dna hypomethylating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC(C)(C)CCNCC* Chemical compound CC(C)(C)CCNCC* 0.000 description 8
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261720346P | 2012-10-30 | 2012-10-30 | |
| PCT/US2013/067607 WO2014070948A1 (en) | 2012-10-30 | 2013-10-30 | Combination therapies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2774296T3 true ES2774296T3 (es) | 2020-07-20 |
Family
ID=50628036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13851971T Active ES2774296T3 (es) | 2012-10-30 | 2013-10-30 | Terapias de combinación para tratar cánceres quimiorresistentes |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20150258068A1 (enExample) |
| EP (2) | EP2914254B1 (enExample) |
| JP (1) | JP6343285B2 (enExample) |
| CA (1) | CA2927565C (enExample) |
| CY (1) | CY1123043T1 (enExample) |
| DK (1) | DK2914254T3 (enExample) |
| ES (1) | ES2774296T3 (enExample) |
| HR (1) | HRP20200521T1 (enExample) |
| HU (1) | HUE048584T2 (enExample) |
| LT (1) | LT2914254T (enExample) |
| PL (1) | PL2914254T3 (enExample) |
| PT (1) | PT2914254T (enExample) |
| RS (1) | RS60122B1 (enExample) |
| SI (1) | SI2914254T1 (enExample) |
| SM (1) | SMT202000168T1 (enExample) |
| WO (1) | WO2014070948A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101127201B1 (ko) | 2003-09-22 | 2012-04-12 | 에스*바이오 피티이 리미티드 | 벤즈이미다졸 유도체와 그의 제조방법 및 약학적 적용 |
| GB0811643D0 (en) | 2008-06-25 | 2008-07-30 | Cancer Rec Tech Ltd | New therapeutic agents |
| WO2012048113A2 (en) | 2010-10-07 | 2012-04-12 | The General Hospital Corporation | Biomarkers of cancer |
| EP3161159B1 (en) | 2014-06-25 | 2020-08-05 | The General Hospital Corporation | Targeting human satellite ii (hsatii) |
| GB201517217D0 (en) | 2015-09-29 | 2015-11-11 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
| GB201517216D0 (en) | 2015-09-29 | 2015-11-11 | Cancer Res Technology Ltd And Astex Therapeutics Ltd | Pharmaceutical compounds |
| AR108257A1 (es) | 2016-05-02 | 2018-08-01 | Mei Pharma Inc | Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas |
| GB201704965D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| GB201704966D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| EP4317972A3 (en) | 2018-02-06 | 2024-03-13 | The General Hospital Corporation | Repeat rna as biomarkers of tumor immune response |
| MA54322A (fr) * | 2018-11-30 | 2021-10-06 | Mei Pharma Inc | Polythérapies pour mds à haut et très haut risque |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| US20100098691A1 (en) * | 2001-01-24 | 2010-04-22 | S'bio Pte Ltd | Combination of benzimidazole anti-cancer agent and a second anti-cancer agent |
| WO2003012085A1 (en) * | 2001-07-30 | 2003-02-13 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Antigen presenting cells, method for their preparation and their use for cancer vaccines |
| JP2005517007A (ja) | 2002-02-07 | 2005-06-09 | アクシス・ファーマスーティカルズ | ヒストンデアセチラーゼ阻害剤としての新規二環式ヒドロキサメート |
| US20040038304A1 (en) | 2002-03-28 | 2004-02-26 | Gala Design, Inc. | Antibody libraries |
| EP1937650B1 (en) * | 2005-09-08 | 2011-06-15 | S*BIO Pte Ltd | Heterocyclic compounds |
| US7700567B2 (en) * | 2005-09-29 | 2010-04-20 | Supergen, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
| JP2012503651A (ja) * | 2008-09-26 | 2012-02-09 | エージェンシー フォー サイエンス，テクノロジー アンド リサーチ | ３−デアザネプラノシン誘導体 |
-
2013
- 2013-10-30 PT PT138519715T patent/PT2914254T/pt unknown
- 2013-10-30 ES ES13851971T patent/ES2774296T3/es active Active
- 2013-10-30 SI SI201331700T patent/SI2914254T1/sl unknown
- 2013-10-30 PL PL13851971T patent/PL2914254T3/pl unknown
- 2013-10-30 RS RS20200355A patent/RS60122B1/sr unknown
- 2013-10-30 WO PCT/US2013/067607 patent/WO2014070948A1/en not_active Ceased
- 2013-10-30 JP JP2015539952A patent/JP6343285B2/ja not_active Expired - Fee Related
- 2013-10-30 DK DK13851971.5T patent/DK2914254T3/da active
- 2013-10-30 EP EP13851971.5A patent/EP2914254B1/en active Active
- 2013-10-30 EP EP19206787.4A patent/EP3662911A1/en not_active Withdrawn
- 2013-10-30 LT LTEP13851971.5T patent/LT2914254T/lt unknown
- 2013-10-30 HR HRP20200521TT patent/HRP20200521T1/hr unknown
- 2013-10-30 HU HUE13851971A patent/HUE048584T2/hu unknown
- 2013-10-30 US US14/440,011 patent/US20150258068A1/en not_active Abandoned
- 2013-10-30 CA CA2927565A patent/CA2927565C/en not_active Expired - Fee Related
- 2013-10-30 SM SM20200168T patent/SMT202000168T1/it unknown
-
2020
- 2020-04-06 CY CY20201100321T patent/CY1123043T1/el unknown
- 2020-12-15 US US17/122,991 patent/US20210100775A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HUE048584T2 (hu) | 2020-08-28 |
| EP2914254A1 (en) | 2015-09-09 |
| CY1123043T1 (el) | 2021-10-29 |
| EP2914254A4 (en) | 2016-06-29 |
| LT2914254T (lt) | 2020-04-27 |
| EP2914254B1 (en) | 2020-01-08 |
| EP3662911A1 (en) | 2020-06-10 |
| SI2914254T1 (sl) | 2020-07-31 |
| JP2016501838A (ja) | 2016-01-21 |
| CA2927565A1 (en) | 2014-05-08 |
| RS60122B1 (sr) | 2020-05-29 |
| CA2927565C (en) | 2021-05-18 |
| PT2914254T (pt) | 2020-04-02 |
| PL2914254T3 (pl) | 2020-09-07 |
| US20150258068A1 (en) | 2015-09-17 |
| JP6343285B2 (ja) | 2018-06-13 |
| US20210100775A1 (en) | 2021-04-08 |
| SMT202000168T1 (it) | 2020-05-08 |
| DK2914254T3 (en) | 2020-03-30 |
| WO2014070948A1 (en) | 2014-05-08 |
| HRP20200521T1 (hr) | 2020-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2914254B1 (en) | Combination therapies to treat chemoresistant cancers | |
| ES2668377T3 (es) | Tratamientos contra el cáncer | |
| ES2365639T3 (es) | Ectoína para el tratamiento de fugas vasculares. | |
| ES2971041T3 (es) | Terapia combinada de inhibidores del receptor 9 de quimiocina C-C (CCR9) y anticuerpos bloqueadores anti-integrina alfa4beta7 para el tratamiento de la enfermedad inflamatoria intestinal | |
| AU2022293208A1 (en) | Use of atr inhibitors in combination with parp inhibitors for treating cancer | |
| JP2012067116A5 (enExample) | ||
| TW201827056A (zh) | 用於預防及／或治療多囊性腎臟病之藥物 | |
| KR101707669B1 (ko) | 약제-내성 종양에서 화학요법제 활성을 증강시키는 ｏｎ01910.ｎａ | |
| CN106822905A (zh) | 含Survivin抑制剂和IRE1抑制剂的药物及用途 | |
| WO2010086964A1 (ja) | がん治療のための併用療法 | |
| WO2019084300A1 (en) | TREATMENT OF GLIOBLASTOMA WITH FASN INHIBITORS | |
| ES2974842T3 (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de nlrp | |
| CA2914742A1 (en) | Handovers with co-operating cells configured to provide coordinated multi-point transmission/reception | |
| ES2978337T3 (es) | Combinación de regonafenib y nivolumab para el tratamiento contra el cáncer | |
| JP2008520682A (ja) | ヒストンデアセチラーゼ阻害剤およびその使用方法 | |
| JP2022533251A (ja) | 患者において血清リン酸塩を低下させるための組み合わせ | |
| WO2014007998A1 (en) | SORAFENIB DERIVATIVES AS p21 INHIBITORS | |
| US20210154265A1 (en) | Pharmaceutical composition, use and method for applying ganoderma microsporum immunomodulatory protein and keyhole limpet hemocyanin in carcinoma treatment | |
| BR112020009596A2 (pt) | combinações de moduladores duplos de irs/stat3 e anticorpos anti pd-1/pd-l1 para tratar câncer | |
| JP2020023447A (ja) | フェニルテトラヒドロピリドインドール誘導体及び医薬組成物 | |
| CA3070878A1 (en) | Combination of midh1 inhibitors and dna hypomethylating agents (hma) | |
| ES2289305T3 (es) | Medicamento para el tratamiento del "sindrome de la respuesta inflamatoria sistemica". | |
| CN104606189B (zh) | 一种化合物在制备mTOR抑制剂中的应用 | |
| US20220016082A1 (en) | Combination therapies for high and very high risk mds | |
| JP2019531317A (ja) | 子宮内膜症の処置のためのインドールの新規誘導体 |